Baptist Health Cancer Care

Manmeet Ahluwalia, MD, MBA, FASCO, shares a message during Brain Cancer Awareness Month.

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing cancer research directly impacts patient care.

Michael E. Kasper, MD, FACRO, discussed unmet needs in skin cancer treatment and addressed misconceptions among patients and health care providers.

Manmeet Ahluwalia, MD, MBA, FASCO, highlights genomic testing as a crucial area of current research with immediate implications for patients with brain cancer.

Noah S. Kalman, MD, MBA, discusses the evolving role of molecular and genetic testing in thyroid cancer management.

In an interview with Targeted Oncology for World Cancer Day, Manmeet Ahluwalia, MD, MBA, FASCO, explored the key challenges facing community oncology and the strategies needed to close these gaps.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma.

An AI-driven tool enhances stereotactic radiosurgery for small brain metastases by predicting local failure risks, optimizing radiation dosing, and personalizing MRI follow-ups.

In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.

Noah S. Kalman, MD, MBA, discusses how oncologists can determine the best course of action for the treatment and management of a patient with thyroid cancer.

Noah S. Kalman, MD, MBA, highlighted advancements in thyroid cancer treatment, emphasizing personalized therapies, molecular testing, and optimizing traditional approaches.

Janelle Vicens, DNP, APRN, FNP-BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow Transplant APP Fellowship.

Noah S. Kalman, MD, MBA, discusses the most common types of thyroid cancer and their respective prognoses.

In an interview with Targeted Oncology, Hina Saeed, MD, discussed how AI and radiomics are changing the landscape of radiation oncology.

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local failure after stereotactic radiosurgery for brain metastases.

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a community oncologist should be aware of.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.

Rohan Garje, MD, provides an overview of a study evaluating how mutations, including TP53, RB1, and PTEN, impact overall survival in patients with metastatic prostate cancer.

Combining stereotactic radiosurgery with immunotherapy significantly improves overall survival in patients with renal cell carcinoma and brain metastasis.

The national shortage of nurses and health care support staff has spilled over to the clinical research space.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the takeaways from a study which examined the impact of various therapies, including combination treatments, for patients with metastatic renal cell carcinoma.

Minesh Mehta, MD, discusses positive findings from the phase 3 METIS trial investigating TTFields therapy for brain metastases in NSCLC.

The novel PPAR-α inhibitor TPST-1120 shows promise for solid tumors, including renal cell carcinoma, as monotherapy and in combination with nivolumab.

In an interview with Targeted Oncology, Manmeet Ahluwalia, MD, MBA, FASCO, discussed the Cancer Moonshot program, its progress, and the next steps.

Guenther Koehne, MD, PhD, highlights the importance of and the key takeaways from the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies.

In an interview with Targeted Oncology, Manmeet S. Ahluwalia, MD, provided insights into his personal career and goals and the transformative potential of oncology.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings from a retrospective study exploring treatment options for geriatric patients with HER2-positive breast cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.